Literature DB >> 3277273

The economic impact of AIDS in the United States.

D E Bloom1, G Carliner.   

Abstract

This analysis of several previous studies of the cost of AIDS suggests that the lifetime cost of medical care per patient will not exceed +80,000, an amount similar to the cost of treating other serious illnesses. If current projections of future AIDS cases are accurate, the cumulative lifetime costs of 270,000 cases diagnosed between 1981 and the end of 1991 will not exceed +22 billion. This amount is small compared with total U.S. medical spending. The economic impact of AIDS on San Francisco, New York, and some other cities, however, is likely to be more serious. The AIDS epidemic will also highlight the financial problems of Americans who face large medical bills without adequate insurance.

Entities:  

Mesh:

Year:  1988        PMID: 3277273     DOI: 10.1126/science.3277273

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  16 in total

1.  A survival analysis of hospitalization among patients with acquired immunodeficiency syndrome.

Authors:  C P Quesenberry; B Fireman; R A Hiatt; J V Selby
Journal:  Am J Public Health       Date:  1989-12       Impact factor: 9.308

2.  Five cases of erroneously diagnosed HIV infection.

Authors:  M J Gill; A Rachlis; C Anand
Journal:  CMAJ       Date:  1991-12-15       Impact factor: 8.262

Review 3.  Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.

Authors:  H D Langtry; K J Palmer; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

4.  Partner notification in the control of human immunodeficiency virus infection.

Authors:  J J Potterat; N E Spencer; D E Woodhouse; J B Muth
Journal:  Am J Public Health       Date:  1989-07       Impact factor: 9.308

5.  Planning community-wide services for persons with HIV infection in an area of moderate incidence.

Authors:  S L Lenker; D P Lubeck; A Vosler
Journal:  Public Health Rep       Date:  1993 May-Jun       Impact factor: 2.792

Review 6.  Defining and measuring the costs of the HIV epidemic to business firms.

Authors:  P G Farnham
Journal:  Public Health Rep       Date:  1994 May-Jun       Impact factor: 2.792

7.  Understanding AIDS: historical interpretations and the limits of biomedical individualism.

Authors:  E Fee; N Krieger
Journal:  Am J Public Health       Date:  1993-10       Impact factor: 9.308

8.  Knowledge, attitudes, beliefs, and behaviors of the business community relative to HIV-AIDS.

Authors:  P G Farnham
Journal:  Public Health Rep       Date:  1991 Nov-Dec       Impact factor: 2.792

9.  The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS.

Authors:  A H Anis; D Guh; R S Hogg; X H Wang; B Yip; K J Craib; M V O'Shaughnessy; M T Schechter; J S Montaner
Journal:  Pharmacoeconomics       Date:  2000-10       Impact factor: 4.981

10.  The impact of HIV-related illness on employment.

Authors:  E H Yelin; R M Greenblatt; H Hollander; J R McMaster
Journal:  Am J Public Health       Date:  1991-01       Impact factor: 9.308

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.